Consultation outcome

Pregabalin and gabapentin: proposal to schedule under the Misuse of Drugs Regulations 2001

This consultation has concluded

Download the full outcome

Pregabalin and gabapentin consultation: our response

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Revised impact assessment

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of outcome

On 13 November 2017, the Home Office asked for views on options whether, and how, to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001. This followed the recommendation by the Advisory Council on the Misuse of Drugs (ACMD) that pregabalin and gabapentin should be controlled as Class C drugs under the Misuse of Drugs Act 1971 (‘the 1971 Act’) and placed in Schedule 3 to the Misuse of Drugs Regulations 2001. The consultation lasted until 22 January 2018 and was UK-wide.

Responses were accepted from members of the public, healthcare professionals, institutions, all sectors within the supply chain including the pharmaceutical industry, wholesalers, and community pharmacies in the UK.

The Home Office is grateful for the views of those who responded to the consultation. On balance, the government is of the view that option 2 – to schedule the drugs under Schedule 3 to the 2001 Regulations but without the safe custody requirements – provides appropriate and necessary safeguards while ensuring that there are not unduly onerous storage requirements for pharmacists, wholesalers and others.

Original consultation

Summary

We are seeking views on controlling the anti-convulsant drugs pregabalin and gabapentin.

This consultation ran from
to

Consultation description

This consultation seeks views on options whether, and how, to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 following the recommendation by the Advisory Council on the Misuse of Drugs (ACMD) that these 2 drugs should be controlled as Class C drugs under the Misuse of Drugs Act 1971 (‘the 1971 Act’) and placed in Schedule 3 to the Misuse of Drugs Regulations 2001.

The consultation is aimed at members of the public, healthcare professionals, institutions, all sectors within the supply chain including the pharmaceutical industry, wholesalers and community pharmacies in the UK.

Comments from all those with an interest in the consultation are welcome.

Please note that the email address below has been corrected. If you have sent a response to this address up to and including 8 December, please resend your response to the email address now stated.

Documents

A consultation on proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Impact assessment

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Impact assessment (signed by the Minister for Crime, Safeguarding and Vulnerability)

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Published 13 November 2017
Last updated 15 October 2018 + show all updates
  1. Response to the consultation and revised impact assessment added.
  2. Email address corrected.
  3. First published.